Literature DB >> 17548036

Adrenal cortical carcinoma--review of current knowledge and treatment practices.

Alexandria T Phan1.   

Abstract

Adrenal cortical carcinoma is a rare endocrine malignancy with a poor long-term prognosis. Accurate diagnosis and preoperative evaluation of the patient presenting with an adrenal mass maximize the opportunity for optimal treatment planning. Surgery still offers the best chance for cure. Despite curability with complete surgical resection, the rate of recurrence is unacceptably high. In metastatic or recurrent disease, systemic treatment options are limited to chemotherapy with or without mitotane. Therapeutic options are often outdated and associated with significant toxicities. A multidisciplinary approach has the best chance for offering optimized management of this lethal disease. Improved understanding of the molecular pathogenesis of this rare malignancy will lead to advancement in the available therapies that may improve this outcome.

Entities:  

Mesh:

Year:  2007        PMID: 17548036     DOI: 10.1016/j.hoc.2007.04.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  13 in total

1.  The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.

Authors:  Antonio M Lerario; Francis P Worden; Carole A Ramm; Elizabeth A Hesseltine; Elizabeth A Hasseltine; Walter M Stadler; Tobias Else; Manisha H Shah; Edem Agamah; Krishna Rao; Gary D Hammer
Journal:  Horm Cancer       Date:  2014-05-22       Impact factor: 3.869

2.  Therapy of adrenocortical cancer: present and future.

Authors:  Daniela F Maluf; Brás H de Oliveira; Enzo Lalli
Journal:  Am J Cancer Res       Date:  2010-12-07       Impact factor: 6.166

3.  Androgen secreting giant adrenocortical carcinoma with no metastases: A case report and review of the literature.

Authors:  Fatih Uruc; Ahmet Urkmez; Ozgur Haki Yuksel; Aytac Sahin; Ayhan Verit
Journal:  Can Urol Assoc J       Date:  2015-09-09       Impact factor: 1.862

4.  Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database.

Authors:  Alexander Kutikov; Katherine Mallin; Daniel Canter; Yu-Ning Wong; Robert G Uzzo
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

5.  A giant non-functional adrenocortical carcinoma presenting with acute kidney injury.

Authors:  Yu-Chen Tseng; Seng-Tang Wu; Tai-Kuang Chao; Ching-Jiunn Wu; Tom Chau; Sung-Sen Yang
Journal:  Int Urol Nephrol       Date:  2013-12-29       Impact factor: 2.370

6.  Current and emerging therapeutic options in adrenocortical cancer treatment.

Authors:  Antonio Stigliano; Lidia Cerquetti; Camilla Sampaoli; Barbara Bucci; Vincenzo Toscano
Journal:  J Oncol       Date:  2012-08-14       Impact factor: 4.375

7.  The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis.

Authors:  Taku Mochizuki; Takashi Kawahara; Daiji Takamoto; Kazuhide Makiyama; Yusuke Hattori; Jun-Ichi Teranishi; Yasuhide Miyoshi; Yasushi Yumura; Masahiro Yao; Hiroji Uemura
Journal:  BMC Urol       Date:  2017-06-29       Impact factor: 2.264

8.  Myxoid and Sarcomatoid Variants of Adrenocortical Carcinoma: Analysis of Rare Variants in Single Tertiary Care Center.

Authors:  Tae Yon Sung; Yun Mi Choi; Won Gu Kim; Yu Mi Lee; Tae Yong Kim; Young Kee Shong; Won Bae Kim; Dong Eun Song
Journal:  J Korean Med Sci       Date:  2017-05       Impact factor: 2.153

9.  Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art.

Authors:  Amir H Lebastchi; John W Kunstman; Tobias Carling
Journal:  J Oncol       Date:  2012-10-18       Impact factor: 4.375

10.  Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma: Usefulness of the Ki-67 Index.

Authors:  Yun Mi Choi; Hyemi Kwon; Min Ji Jeon; Tae-Yon Sung; Suck Joon Hong; Tae Yong Kim; Won Bae Kim; Young Kee Shong; Jae Lyun Lee; Dong Eun Song; Won Gu Kim
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.